Using a deep learning approach to study mutations in target sites of RNA-binding proteins, researchers identified DDHD2 as a candidate schizophrenia risk gene.
Tempus is developing a new predictive bioinformatics model to improve clinical trial enrollment for Janssen, while the pharma firm has joined Tempus' TIME Trial.
University spinout PercayAI will analyze genomic and clinical data from WUSTL's McDonnell Genome Institute in search of potential coronavirus drug combinations.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
In a PrecisionFDA challenge, DeepVariant calls of PacBio HiFi reads topped 99 percent precision and recall for SNVs and indels, bringing HiFi in line with Illumina.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
